Fully vaccinated Americans may need to receive additional COVID-19 boosters this fall, according to the Food and Drug Administration’s Dr. Peter Marks. The agency’s advisory committee will meet on April 6 to discuss the future of booster shots. (CNBC Weekly)
Roche’s experimental anti-TIGIT cancer immunotherapy, tiragolumab, failed in a late-stage clinical trial. In a statement, the company said it was “disappointed” by the results but planned to examine further Phase III data at a later date. (STAT)
Sanofi is paying $150 million upfront for IGM Biosciences’ IgM antibody technology platform, and up to $6 billion more in potential milestones. The acquisition is part of Sanofi’s goal to bolster its oncology, immunology and inflammation pipelines. (Endpoints News)
The FDA has approved a higher dose of Novo Nordisk’s Ozempic to treat type 2 diabetes. The drug is now approved for 0.5 mg, 1 mg and 2 mg doses. (Reuters)
CVS Health will pay $484 million to settle claims related to the opioid epidemic in Florida. It represents the first time the company has settled a government lawsuit linked to the crisis. (The Wall Street Journal)
